aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
BioRay Pharmaceuticals is a leading biopharmaceutical company in China, specializing in discovering, developing, manufacturing, and commercializing medicines for immune-mediated diseases and cancer. Leveraging expertise in immunology, BioRay offers a diverse portfolio targeting various therapeutic areas and cellular pathways to deliver life-changing treatments.
BioRay has achieved significant milestones in the biopharmaceutical industry, including the successful commercialization of multiple therapies. The company’s impact is evident in its commitment to improving patient outcomes for those living with autoimmune diseases and cancer.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Pharmaceuticals, Medicines
Technology
Biotech
Tags
Healthtech
Model Types
Hardware, Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise, Government
Geographic Exposure
Global
When was BioRay Pharmaceuticals founded?
BioRay Pharmaceuticals was founded in 2019.
Where is BioRay Pharmaceuticals’s headquarters located?
BioRay Pharmaceuticals’s headquarters is located in Shanghai, CN.
When was BioRay Pharmaceuticals’s last funding round?
BioRay Pharmaceuticals’s most recent funding round was for $1.5B (USD) in January 2023.
How many employees does BioRay Pharmaceuticals have?
BioRay Pharmaceuticals has 3000 employees as of Feb 10, 2024.
How much has BioRay Pharmaceuticals raised to-date?
As of July 05, 2023, BioRay Pharmaceuticals has raised a total of $2.5B (USD) since Jan 4, 2023.
Add Comparison
Total Raised to Date
$2.5B
USD
Last Update Jan 4, 2023
Last Deal Details
$1.5B
USD
Jan 4, 2023
Private Equity
Total Employees Over Time
3000
As of Feb 2024
BioRay Pharmaceuticals Address
Shanghai,
317700
People's Republic of China
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts